By: Adam Feuerstein | 08/12/14 - 05:11 PM EDT
Updated with new information from the conference call
Arrowhead Research (ARWR) just released interim results from a mid-stage study of its experimental RNA interference therapy for hepatitis B. The announcement is short on specific details but the Arrowhead drug, ARC-520, appears to have passed through its first clinical hurdle in hepatitis B patients relatively well.
Arrowhead shares closed Tuesday at $13 ahead of the ARC-520 data announcement. The stock is down 5% to $12.25 in the after-market session, reflecting some uncertainty about the results, perhaps confusion or frustration over why the company chose not to be more forthcoming with actual numbers.
I wrote a preview of the ARC-520 data recently. Here's how Arrowhead describes the ARC-520 results today:
-- Initial blinded data suggest that the magnitude of HBsAg knockdown is similar to non-human primate studies, including the chronically infected chimpanzee reported on previousl
-- Duration of knockdown appears to be substantially more sustained than in non-human primates, with patients in the 2 mg/kg group still demonstrating substantial knockdown after 8 weeks, which is the most recent time point available.
-- HBsAg levels appear to continue to decline in a number of patients at the 8 week time point in the 2 mg/kg group
12/16/14 - 11:20 AM EST
12/15/14 - 09:23 AM EST
12/03/14 - 04:01 PM EST
12/03/14 - 01:31 PM EST
12/02/14 - 04:34 PM EST
12/16/14 - 19:00 PM EST
12/16/14 - 15:08 PM EST
12/16/14 - 11:01 AM EST
12/15/14 - 19:00 PM EST
12/15/14 - 11:32 AM EST
Access the tool that DOMINATES the Russell 2000 and the S&P 500.